Biogen (BSP:BIIB34) Debt-to-Equity

: 0.48 (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

Biogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was R$0 Mil. Biogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was R$34,427 Mil. Biogen's Total Stockholders Equity for the quarter that ended in Mar. 2023 was R$71,861 Mil. Biogen's debt to equity for the quarter that ended in Mar. 2023 was 0.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biogen's Debt-to-Equity or its related term are showing as below:

BSP:BIIB34' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 0.78
Current: 0.48

During the past 13 years, the highest Debt-to-Equity Ratio of Biogen was 0.78. The lowest was 0.01. And the median was 0.13.

BSP:BIIB34's Debt-to-Equity is ranked worse than
62.59% of 834 companies
in the Drug Manufacturers industry
Industry Median: 0.31 vs BSP:BIIB34: 0.48

Biogen Debt-to-Equity Historical Data

The historical data trend for Biogen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.46

0.48

0.73

0.70

0.49

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity																0.68	0.64	0.52	0.49	0.48

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biogen's Debt-to-Equity falls in comparison to its industry or sector. The grey bar indicates the Debt-to-Equity's extreme value range as defined by GuruFocus.

Biogen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biogen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	34693.076)	/	70277.345
	=	0.49

Biogen's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	34427.283)	/	71860.971
	=	0.48

Biogen (BSP:BIIB34) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biogen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biogen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines